<DOC>
	<DOCNO>NCT00771810</DOCNO>
	<brief_summary>This research study investigate safety effectiveness two different dose level new , unapproved drug give along chemotherapy regimen gemcitabine carboplatin gemcitabine cisplatin prescribed woman treatment ovarian cancer . This experimental drug call TXA127 test effectiveness see help reduce side effect chemotherapy , primarily low blood platelet level lead excess bleeding . This study also intend test safety TXA127 give injection skin daily basis concurrently 6 cycle prescribe chemotherapy .</brief_summary>
	<brief_title>Study Drug Reduce Thrombocytopenia Patients Receiving Chemo Ovarian , Fallopian Tube Peritoneal Cancer</brief_title>
	<detailed_description>This Phase IIb , multicenter , randomize , double-blind , placebo-controlled study compare safety efficacy two dose level TXA127 administer 6 cycle combination gemcitabine platinum-based chemotherapy . This study intend investigate effectiveness TXA127 mitigation severity and/or incidence thrombocytopenia , well safety administer self-injected , subcutaneous solution . Females 18 year age old confirm diagnosis ovarian carcinoma schedule undergo combination chemotherapy gemcitabine carboplatin gemcitabine cisplatin consider study . Subjects may chemotherapy naïve , newly diagnose , post single course chemotherapy follow progression- treatment-free interval least 3 month , post 2 previous course chemotherapy progression- treatment-free interval least 6 month . Subjects randomize 1:1:1 ratio one follow three blind treatment group : placebo , 100 ug/kg/day TXA127 300 ug/kg/day TXA127 . Treatment concurrent six consecutive 21-day cycle one follow gemcitabine platin regimen : Regimen A - Intravenous cisplatin therapy dose 30-50 mg/m2 give Day 1 cycle - Intravenous gemcitabine dose 800 mg/m2 give Day 1 cisplatin Day 8 cycle . Regimen B - Intravenous gemcitabine dose 1000 mg/m2 give Days 1 8 cycle - Intravenous carboplatin AUC 4 give gemcitabine Day 1 cycle TXA127 self-administered subcutaneous injection subject daily Days 2-6 9-15 cycle chemotherapy . Blood specimens draw hematologic analysis Days 1 , 8 15 treatment cycle .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lymphopenia</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>Females least 18 year age ovarian carcinoma one following : Newly diagnose ovarian cancer chemotherapy naïve , Post single previous course chemotherapy , 3month diseaseprogression treatmentfree interval , exception antibody therapy , prior study screen visit , Post two previous course chemotherapy 6month diseaseprogression treatmentfree interval , exception antibody therapy , prior study screen visit . Must schedule course combination chemotherapy consist gemcitabine cisplatin gemcitabine carboplatin administer 21day cycle Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Adequate bone marrow , renal , hepatic function measure standard chemistry hematology blood test Adequate blood coagulation parameter measure standard blood test coagulation Any clinical laboratory abnormality great Grade 2 toxicity ( NCI criterion ) , exception laboratory parameter specify inclusion criterion Significant unstable cardiovascular disease Uncontrolled high blood pressure Current use angiotensin convert enzyme ( ACE ) inhibitor angiotensin II antagonists Evidence metastatic disease bone Metastatic disease CNS require treatment radiation therapy Uncontrolled infection ( ) Radiation therapy chemotherapy ( except specify inclusion criterion ) within previous 5 year Concurrent use hematopoietic erythropoietic agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Cytopenia</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>